DEBBIE GARZA

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation. H.R. 6 - the 21st Century Cures Act, all provisions related to retail pharmacy, including waste, fraud, and abuse prevention in Medicare Part D and drug price calculations.

S.754 - the Cybersecurity Information Sharing Act of 2015, all provisions related to liability protection for electronic sharing of cyber threat indicators with the federal government.

H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.

H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.

H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R.4069 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2013," all provisions related to changes to the registration process under the Controlled Substances Act and the establishment of the Combatting Prescription Drug Abuse Working Group.

H.R.4069 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2013," all provisions related to changes to the registration process under the Controlled Substances Act and the establishment of the Combatting Prescription Drug Abuse Working Group.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.

S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.

S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.

S. 2862 - "Regulatory Transparency, Patient Access and Effective Drug Enforement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.H.R. 4709 - the "Ensuring Patient Access and Effective Drug Enforcement Act of 2014," all provisions related to changes to the registration process under the Controlled Substances Act and the report to Congress on the effects of law enforcement activities on patient access to medications.

Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

Issues related to United States corporate tax reform - no specific legislation.S. 336 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

H.R. 4190 - all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communitites, consistent with state scope of practice laws.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist in health care delivery. No specific legislation

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist federally in health care delivery. No specific legislation

S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. Issues related to related to pharmacists recognized as health care providers federally. No specific legislation

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.Issues related to related to pharmacists recognized as health care providers federally. No specific legislation Issues related to Pharmacy Benefit Managers (PBM) activities around disclosures and audit protections. No legislation.

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist federally in health care delivery. No specific legislation

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.Issues related to related to pharmacists recognized as health care providers federally. No specific legislation Issues related to Pharmacy Benefit Managers (PBM) activities around disclosures and audit protections. No legislation.

S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. Issues related to related to pharmacists recognized as health care providers federally. No specific legislation

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist in health care delivery. No specific legislation

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. Issues related to related to pharmacists recognized as health care providers federally. No specific legislation

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist in health care delivery. No specific legislation

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare. Issues related to expansion of the role of a pharmacist federally in health care delivery. No specific legislation

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.

S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available. P.L. 111-148 - the "Patient Protection and Affordable Care Act," all provisions regarding the implementation of regulations of P.L. 111-148, including issues related to Average Manufacturer's Price (AMP), Medication Therapy Management (MTM), employer coverage mandates, pilot programs and demonstration projects.

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescription drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 6638, the Supporting Access to Formulated and Effective (SAFE) Compounded Drugs Act, all provisions requiring compounding pharmacies to register their facility with the FDA, requiring compounded drugs to be labeled appropriately, establishing an FDA database on compounding pharmacies and having the FDA set minimum production standards. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit the PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan, or to control the costs of such coverage, unless the manager satisfies specified PBM audit and disclosure requirements. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.

H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," all provisions regarding requiring each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under each plan. H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites.

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available. P.L. 111-148 - the "Patient Protection and Affordable Care Act," all provisions regarding the implementation of regulations of P.L. 111-148, including issues related to Average Manufacturer's Price (AMP), Medication Therapy Management (MTM), employer coverage mandates, pilot programs and demonstration projects.

H.R. 2529/S.1368 - the "Restoring Access to Medication Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limits payments for medications from health savings accounts, medical savings accounts, and health felxible spending arrangements to only prescriotion drugs or insulin.

H.R. 2529/S.1368 - the "Restoring Access to Medication Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limits payments for medications from health savings accounts, medical savings accounts, and health felxible spending arrangements to only prescriotion drugs or insulin. H.R. 5651 - the FDA Reform Act of 2012, all provisions regarding reauthorizing and establishing new FDA prescription drug user-fee programs and revises requirements related to prescription, pediatric and generic drugs; medical devices; biosimilar biological products; new infectious disease drugs and drug manufacturer reporting. H.R. 5842 - the Restoring Access to Medication Act, all provisions regarding repealing provisions of PPACA that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. H.R. 436 - the Health Care Cost Reduction Act, all provisions regarding repealing provisions of PPACA that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. S.3187/S.2516 - the FDA Safety and Innovation Act, all provisions regarding reauthorizing and establishing new FDA prescription drug user-fee programs and revises requirements related to prescription, pediatric and generic drugs; medical devices; biosimilar biological products; new infectious disease drugs and drug manufacturer reporting.

H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," all provisions regarding requiring each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under each plan. H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites.

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit the PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan, or to control the costs of such coverage, unless the manager satisfies specified PBM audit and disclosure requirements. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.

H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.

H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.

H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales.

H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales. Issues related to corporate tax reform. No specific legislation.

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available. P.L. 111-148 - the "Patient Protection and Affordable Care Act," all provisions regarding the implementation of regulations of P.L. 111-148, including issues related to Average Manufacturer's Price (AMP), Medication Therapy Management (MTM), employer coverage mandates, pilot programs and demonstration projects.

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit the PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan, or to control the costs of such coverage, unless the manager satisfies specified PBM audit and disclosure requirements. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.

H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," all provisions regarding requiring each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under each plan. H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites.